Search

ONCO3R B2 Patent - Heterocyclic Compounds and Pharmaceutical Compositions for Disease Treatment

The USPTO granted US Patent 12,606,554 B2 to ONCO3R Therapeutics BV on April 21, 2026. The patent covers heterocyclic compounds according to Formula I and pharmaceutical compositions for treating inflammatory, autoinflammatory, autoimmune, proliferative, fibrotic diseases, transplant rejection, and diseases involving impairment of cartilage or bone turnover, as well as conditions associated with hypersecretion of IL-6, TNFα, interferons, IL-12 and/or IL-23. The patent contains 19 claims and was filed on May 25, 2020.